<div id="readability-page-1">04:38 AM EST, 11/26/2025 (MT Newswires) -- Nyxoah SA ( NYXH ) said Wednesday that the US Centers for Medicare &amp; Medicaid Services has approved a new reimbursement rule, increasing the reimbursement rate applicable to the company's Genio neurostimulation therapy for obstructive sleep apnea.Effective Jan. 1, 2026, hospital outpatient department reimbursement for the code applicable to Genio will rise 48% to $45,000, while ambulatory surgery centers facility reimbursement will increase 58% to $42,373, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

NYXH

Nyxoah SA 宣佈，美國醫療保險和醫療補助服務中心已批准一項新規則，提高其用於治療阻塞性睡眠呼吸暫停的 Genio 神經刺激療法的報銷率。從 2026 年 1 月 1 日起，醫院門診部門的報銷將增加 48%，達到 45,000 美元，而門診手術中心的設施報銷將增加 58%，達到 42,373 美元

Nyxoah 在新的 CMS 規則下獲得了對 Genio 療法的更高報銷框架